"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

> 02nd - 04th October 2018, Double Tree Suites By Hilton Boston, Cambridge, Massachusetts, USA

Key Speakers Include



DAVID HUTCHINSON Founder **Brookwood International Academy**

SUZANNE SCHRANDT **Director, Patient Engagement Arthritis Foundation**



MELVA T. COVINGTON Principal AGAPE Strategic Solutions



SHEILA WEISS Senior Research Leader **Evidera**

SHEETAL KHEDKAR Senior Director, Regulatory Science Sarah Cannon Development Innovations



STEPHEN F. AMATO



Faculty Director Graduate Regulatory Affairs, Market Access and Life Sciences Northeastern University

Plus many more COMING SOON

WHO ATTENDS?





TEGINDER SINGH Senior Director Global Regulatory Affairs

Executive Director, Clinical Safety Statistics



ALEXANDRE KIAZAND **Global Head Safety Science** AstraZeneca

WILLIAM WANG

Johnson & Johnson

Merck



RICHARD WOLF Head of GCSP Regions & PV Operations CSL Behring



MICK FOY Group Manager MHRA (UK)



DEEPA ARORA Vice President - Pharmacovigilance & Global Head-Drug Safety & Risk Management Lupin (India)



KHAUDEJA BANO

Senior Medical Director Medical Affairs Abbott

DOUG COFFMAN

Chief of Staff/Senior Director, Strategy & Business Planning - Global Patient Safety Evaluation Takeda Pharmaceuticals

MATTHEW MELDORF

Senior Group Medical Director, Safety Science Genentech



ANAND ANANTHAKRISHNAN Director, Pharmacovigilance Safety System **Fresenius Medical Centre**



Sr. Director, Pharmacoepidemiology Team Lead Sanofi Genzyme




PEDRO L. OYUELA Medical Director, Global Patient Safety Amgen

ANNAYA BHATTACHARYA Director Global IO Implementation Lead **Bristol-Myers Squibb**



Vice President- Head of Patient Safety and Pharmacovigilance Kite Pharma, A Gilead Company



Director, Clinical Research **CHDI Foundation**

Organized by





🌐 info.uk@virtueinsight.com







#VIphv

"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

> 02nd - 04th October 2018, Double Tree Suites By Hilton Boston, Cambridge, Massachusetts, USA

"The Breadth of expertise from Industry was exceptional"

PV Audit Manger, Allergan

CONFERENCE INTRODUCTION:-

Global Pharmacovigilance Market expected to Reach US\$6.1 bn by 2020 expanding at a CAGR of 14.2% from 2015 to 2020 and also expected to reach a market size of \$8.23 billion by 2022. By 2020, the size of the global pharmaceutical market is anticipated to grow to USD 1.3 trillion, with the E7 countries -- Brazil, China, India, Indonesia, Mexico, Russia and Turkey

16th Pharmacovigilance 2018 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case studies and industry experiences. This conference will help the drug safety representatives from the pharmaceutical industry and academic and quality research organizations who wish to understand how to avoid common deficiencies in inspections by learning from the experiences of others; to gain a greater understanding of new and existing pv requirements, and to improve their organizations' compliance with pv requirements. Also it can help you control your product's lifecycle, your patient's trust, and your revenue. Hence, this conference will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting Pv development. What does the future hold for pv? Find out at our conference on opportunities and activities shaping pv to 2020 with respect to regulations, technologies and services. Learn and know on what are drug producers and service providers doing? What regulations and technologies influence the current PV field? You can also discover at 16th Pharmacovigilance 2018 on spending forecasts for PV (US, the EU and Asia).

It gives me great pleasure in welcoming all of you to the Virtue Insight's 16th Pharmacovigilance 2018. I wish and pray that all our efforts will be beneficial to our industries and to our country at large.

AN EVENT TO VOW

16th Pharmacovigilance 2018 - "Uniting "Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicat-

ed networking drinks time, meet the leading international vendors show-

casing the products of tomorrow in the co-located exhibition. Expand your

knowledge of the latest business models and strategies in the high-level

conference. Whether you are on the branded or generic side, you cannot

afford to miss this opportunity to benchmark your tactics and strategies against the industry leaders who will be the first to traverse the pathway.

Devise an immediate action plan for your biosimilar prosecution and liti-

gation strategies in light of the barriers to entry, research and development

costs, and regulatory hurdles, which are balanced against an enormous po-

KEY THEMES DISCUSSED IN THIS CONFERENCE:-

- Pharmacovigilance in the US: What comes next for the industry?
- Recent developments legislation, policies, systems, technology, communication strategies and best practice in PV
- Optimising the overall PV ecosystem Challenges and Opportunities
- Why does pharmacovigilance sometimes fail and where could the fault lie?
- Pharmacovigilance and healthcare system
- Technology Impact Cloud Big data Analytics AI Machine learning Updates to PSUR, PBRERs, DSUR, PASS
- Good Clinical Practices and Good Pharmacovigilance practices
- Future of outsourced phase I, II and III trials and post-marketing studies,
- Data quality management and analysis analyzing the new guidelines
- Strategies to improve clinical trials and PV
- Maintaining proper balance in relationships: Sponsor Site CRO & Patients
- Patient centric approach to help improve patient safety Outsourcing activities Choosing your right vendor and setting the path right
- PV Audit & inspections preparation, implementation and lessons to be learnt Discover approaches for collecting, integrating and analyzing all of the safety
- data generated from preclinical models
- Current regulations and guidelines USA, EU and RoW
- The developing regulatory framework in advanced and developing markets
- Be part of a major networking opportunity

WHY EXHIBIT?

tential for increased profit margins.

Make Sales Debut new products Profile your brand Meet new business partners Develop key relationships Educate pharma and biotech companies



WHO WILL YOU MEET

CEO's, CTO's, CIO's, Presidents, VPs, Directors, Heads, Managers, Scientific Advisors, Consultants of:

Pharmacovigilance, Pharmacoepidemiology, Pharmacogenomics, Drug/Product Safety, Drug Development, Information and Clinical Data Management, Clinical Pharmacology, Clinical Safety, Periodical safety update Reports, Risk Management, Research & Development, Quality Assurance, Patient Safety, Signal Detection, Safety Surveillance, Outcomes Research, Data Analysis, Epidemiology, Medical Affairs, Regulatory Affairs and Compliance, Information technology, Sales and Marketing

Organized by



+44-2036120886

"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

> 02nd - 04th October 2018, Double Tree Suites By Hilton Boston, Cambridge, Massachusetts, USA

"Very nice opportunity to share own challenges with other Pharmacovigilance experts and hear about future initiatives. I would like to thank Virtue Insight for organising the conference"

Associate Director, Pharmacovigilance Operations, INCYTE Biosciences International

AGENDA AT A GLANC

DAY ONE - 02nd October 2018

WORKSHOP - SUMMARY

New European Regulations impacting global clinical trials

Radical changes to the way trials will be authorized and performed in Europe will have a major effect on sponsors undertaking clinical trials in Europe. Add to this strict new EU data protection laws which affect data transfers to the USA – you need to be aware!

This must attend half day session – with interactive Q&A's using keypads – will be delivered by globally renowned clinical research and GCP trainer, Prof Dr David Hutchinson. It will provide key facts on the new requirements and allow participants to make sure that they are prepared for the changes.

- The EU Clinical Trial Regulation 2014/536 overview and impact for sponsors and investigators performing trials in Europe. Changes
 include using an electronic portal to obtain a single authorization with no direct contact with ethics committees! This Regulation will
 replace current clinical trial legislation.
- Overview of the new EU General Data Protection Regulation tough new requirements affecting subjects' rights, data processing and transfer with massive fines for breaches!
- How Brexit will affect clinical trials in Europe and the UK as the UK prepares to leave the EU in 2019 we look at the likely impact will this have on trials and marketing authorisations in the UK

All participants will receive a book entitled "A Guide to European Data Protection" and an opportunity to do an online training module, free of charge.

WORKSHOP - SCHEDULE

New European Regulations impacting global clinical trials

- 10.00 Introduction and icebreaker
- 10.15 The EU Clinical Trial Regulation 2014/536 overview and impact for sponsors and investigators performing trials in Europe
- 11.15 Break
- 11.30 Overview of the new EU General Data Protection Regulation Followed by a short presentation on – How Brexit will affect clinical trials and requirements in Europe and the UK
- 12.30 Questions and discussion
- 13.00 Lunch & Close

DAVID HUTCHINSON, Founder and Academic Dean, Brookwood International Academy, Visiting Professor of Clinical Research & GCP, University of Surrey, UK



"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

> 02nd - 04th October 2018, Double Tree Suites By Hilton Boston, Cambridge, Massachusetts, USA

"Good opportunity to network with colleagues. Mostly the speakers/panel members were of high calibre and experienced."

Safety Executive Director, Amgen

AGENDA AT A GLANCE

08:30 – Coffee and registration – An opportunity to meet and network with your conference colleagues.

09:30 BEN LOCWIN President Healthcare Science Advisors

Chairperson opening remarks

MARKET TRENDS & WAY FORWARD

09:40 Morning Keynote Address 1 - Strengthening and rationalizing Pharmacovigilance in the US: where are we heading?

- Pharmacovigilance in the US: What comes next for the industry?
- Updates from the Office of Surveillance and Epidemiology (OSE) within CDER.
- Postmarketing safety monitoring
- Does the shift towards emerging markets pose a risk to drug safety and biased data reports?

QUALITY - SAFETY

10:20 Morning Keynote Address 2 - Achieving quality and safety in an optimized pv management

- · How to keep your safety department's focus and driver's right?
- How optimized PV management & risk minimization procedures can ensure drug safety
- How to meet the recommendation for safety assessment committees
- · Risk based approaches to pharmacovigilance

10:50 - Morning Coffee/Tea & Discussion

11:10 KHAUDEJA BANO Senior Medical Director Medical Affairs Abbott

Impact of Combination product post market safety reporting on PV

CHALLENGES & OPPORTUNITIES

- 11:40 Keynote Panel Discussion: Optimising the overall PV ecosystem - Challenges, Opportunities and Newer directions
- Challenges and Opportunities for effective Pharmacovigilance in the 21st Century

+44-2036120886

🌐 info.uk@virtueinsight.com

Organized by



29 Gary Court, 189 London Roa Croydon, Surrey CR0 2D

DAY TWO - 03rd October 2018

- Update on PV in EU, USA & RoW Current and new trends for PV, and future guidelines
- Globalization of Pharmacovigilance
- Creating a proactive drug safety culture
- Where is the market heading and what needs to be done?
- Strategies to stay ahead of the curve
- How Automation and AI can be used in PV
- Pharmacovigilance The effect of Brexit

Moderator:

BEN LOCWIN President

Healthcare Science Advisors

Panellists:

12:20

MELVA T. COVINGTON Principal AGAPE Strategic Solutions

MATTHEW MELDORF Senior Group Medical Director, Safety Science Genentech

ANAND ANANTHAKRISHNAN

Director, Pharmacovigilance Safety System Operations Fresenius Medical Centre

> DAVID HUTCHINSON Founder

Brookwood International Academy

Impact on GDPR on pharmacovigilance

Massive fines for breaching the new EU General Data Protection Regulation effective from May 2018. What is its impact on pharmacovigilance activities?

12:40 – Networking luncheon

13:40 DAVID CHONZI

Vice President- Head of Patient Safety and Pharmacovigilance Kite Pharma, A Gilead Company

Crisis management within drug safety

- Regulations & Guidelines in connection with serious safety issues
- What determines a crisis?
- · Communications to Regulators what is required
- Communications within the company
- What happens next?

14:10 WILLIAM BLUMENTALS Sr. Director, Pharmacoepidemiology Team Lead

Sanofi Genzyme

Achieving Efficiency – Using Claims or Electronic Medical Records Databases to Address Background Event Rates

 Claims databases and electronic medical records are often underutilized in favor of literature reviews for the rapid evaluation of safety signals

"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

> 02nd - 04th October 2018, Double Tree Suites By Hilton Boston, Cambridge, Massachusetts, USA

"The session was knowledge transfer/sharing and valuable too"

Associate Manager, IQVIA (formerly known QuintilesIMS)

AGENDA ' A GLANCE

DAY TWO - 03rd October 2018

- Existing data sources may provide more detailed information on disease incidence and disease associations
- Use of existing data sources can potentially expedite the signal evaluation process

14:40 / Solution Provider Presentation

For sponsorship opportunities please contact info.uk@virtueinsight.com

15:00 - Afternoon Tea/Coffee

15:20 MICK FOY Group Manager MHRA (UK)

"WEB-RADR II, integrating mobile technologies for improved pharmacovigilance"

- How to mobilise ADR data collection
- · Two way communication for effective stakeholder engagement
- Effective use of e-health for PV
- Bringing new technologies to low and middle income countries

16:00 / DOUG COFFMAN

Chief of Staff/Senior Director, Strategy & Business Planning - Global Patient Safety Evaluation Takeda Pharmaceuticals

Successful vendor oversight program

Pharma and Biotech companies continue to outsource more work in effort to focus in-house resource on the most strategic activities. This operating model has led to an increase in the scope of service that suppliers are taking on to support Pharmacovigilance activities. Given the expectation from global regulators and other stakeholders to have Pharma and Biotech companies accountability for delegated activities, implementing an appropriate vendor oversight framework is critical. This discussion will focus on the key elements that make up a successful vendor oversight program.

SPONSOR - SITE - CRO - PATIENTS

16:30 Panel Discussion – Maintaining proper communication between - Sponsor – Site – CRO & Patients

- Importance of proper communication between Sponsor Site - CRO & Patients
- Working together to improve drug safety
- Patients involvement for a better PV knowledge Patient support programs
- Mistakes that will doom a CRO-Supplier partnership
- How poor communication, patient recruitment plague clinical Trials

Moderator:

BEN LOCWIN President Healthcare Science Advisors

Panellists:

RICHARD WOLF Head of GCSP Regions & PV Operations CSL Behring

WILLIAM BLUMENTALS Sr. Director, Pharmacoepidemiology Team Lead Sanofi Genzyme

17:10 - Chairperson's closing remarks and end of conference

17:20 - 18:20 Networking Drinks - Take your discussions further & build new relationships in a relaxed & informal setting

NETWORKING DRINKS



Meet with your industry peers for a relaxed drink at the end of day one

FOR DELEGATE REGISTRATIONS:-

Our potent conference agenda delivering the latest information and the world class leaders as speakers attract delegates to attend from around the world. We aim for our attendees to be equipped with knowledge of latest developments & enable them to network with the industry key personnel.

Delegate Registration - delegate.uk@virtueinsight.com

Organized by



29 Gary Court, 189 London Road Croydon, Croydon,

"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

> 02nd - 04th October 2018, Double Tree Suites By Hilton Boston, Cambridge, Massachusetts, USA

"Thanks Virtue Insight Piyush Patel for providing the stupendabulous experience of 13th Pharmacovigilance Conference in Chicago (27-28 Sep). Really worth attending this platform which constituted of wonderful people of the industry around from brilliant experience and background. Very well planned and coordinated; flawless activities all 2 days long. All the best to you and the team for events ahead."

Region Head, Business Development and Program Delivery, Turacoz Healthcare Solutions

AGENDA AT A GLANCE

DAY THREE - 04th October 2018

08:30 – Coffee and registration – An opportunity to meet and to network with your conference colleagues.

09:30 BEN LOCWIN President Healthcare Science Advisors

Chairperson opening remarks

SIGNAL DETECTION

09:40 WILLIAM WANG Executive Director, Clinical Safety Statistics Merck

Morning Keynote Address 1 - Signal detection & management

- Challenges of signal detection in spontaneous reporting
- What are the new technologies to determine the risk in PV signal detection?
- Aligning expectations between industry and regulators on signal detection and investigation
- · How to monitor safety in blinded clinical trials
- Statistical approaches to looking at blinded data and detecting signals
- Signals validated by MAHs procedural options
- Signal Detection: Innovations and challenges

OUTSOURCING

10:10 ANAND ANANTHAKRISHNAN Director, Pharmacovigilance Safety System Operations Fresenius Medical Centre

PV and Outsourcing - Hosted vs On premise safety databases - challenges and considerations for effective management of them

- Preliminary set up steps what are all to be looked into?
- Moving forward what are the deals that are to be communicated
- Steps to be taken in order to maintain efficacy and quality
- Monitoring constantly and effects of proper communication
 Benefits and risks of managing a pharmacovigilance-out
 - sourced organization

BUSINESS MODELS

10:40 / Solution Provider Presentation

For sponsorship opportunities please contact info.uk@virtueinsight.com

11:00 - Morning Coffee/Tea & Discussion

Organized by



29 Gary Court, 189 London Road Croydon,

() +44-2036120886

🌐 info.uk@virtueinsight.com

11:20 / Solution Provider Presentation

For sponsorship opportunities please contact info.uk@virtueinsight.com

IMPACT OF TECHNOLOGY

11:40 Next generation technology - Opportunities in Pharmacovigilance

- Emerging technologies to efficiently collect, store and analyze data in a comprehensive data management system
- Opportunities for PV Software Services companies
- Cloud Big data Analytics AI Machine learning
- The value of machine learning in safety
- Use of mobile technologies and social media in pharmacovigilance

PV - RISK MANAGEMENT & PLANNING

12:10 Panel Discussion - Evaluating risk management requirements - What and how to do?

- Requirements of risk management plans from an industry point of view
- How to put Benefit-risk assessments into practice?
- How to write a successful risk management plan?
- Including the patient in the benefit: risk assessment at an early stage in drug development?
- Improving risk:benefit assessment with comprehensive data and a quality, compliant safety system
- How to strengthen your organization by leveraging your safety platform?

Moderator:

BEN LOCWIN

President Healthcare Science Advisors

Panellists:

WILLIAM WANG

Executive Director, Clinical Safety Statistics Merck

PEDRO L. OYUELA Medical Director, Global Patient Safety Amgen

ANNAYA BHATTACHARYA Director Global IO Implementation Lead Bristol-Myers Squibb

ANKA G. EHRHARDT

Director, Clinical Research CHDI Foundation

"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

> 02nd - 04th October 2018, Double Tree Suites By Hilton Boston, Cambridge, Massachusetts, USA

"Content very relevant. I learnt many things / got clarification on several points."

Sr. Manager PVCompliance, Gilead Sciences

AGENDA AT A GLANCE

DAY THREE - 04th October 2018

SUZANNE SCHRANDT Director, Patient Engagement Arthritis Foundation

SHEILA WEISS Senior Research Leader Evidera

12:50 – Networking luncheon

PATIENT CENTRIC

14:00 ALEXANDRE KIAZAND Global Head Safety Science AstraZeneca

Safety Science: Integrative Approach to Patient Safety

- Investing in safety- How failures in safety programs have resulted in in of more than half of all project closures in pharmaceuticals?
- How to predict clinical reactions to the drugs by integrating pharmacology, subject's predisposition, and drug structure to mitigate ADE's
- How a thorough understanding of target, drug structure, and pharmacology at discovery can help predict up to 75% of the adverse drug reactions in the market

DATA COLLECTION & QUALITY CONTROL

14:30 / DEEPA ARORA

Vice President - Pharmacovigilance & Global Head-Drug Safety & Risk Management Lupin (India)

Data quality management and analysis – Analysing the new guidelines

- Describe electronic case reporting to Adverse Event Reporting System
- Explain data quality issues encountered with electronic ICSR submissions
- Discuss data quality issues related to suspect product identification, using examples
- Discuss data quality issues related to MedDRA coding for adverse events and medication errors, using examples
- Periodic Benefit-Risk Evaluation Report

15:00 Data sources for signal detection: Advantages, limitations and relevant challenges

- Signal detection Both clinical trials and post marketing data
- Discussion of different signal detection methods available
- Medical context into signal detection approaches to automate qualitative signal detection

15:30 - Afternoon Tea/Coffee

Organized by



29 Gary Court, 189 London Roa Croydon,

() +44-2036120886

🌐 info.uk@virtueinsight.com

PV AUDIT & INSPECTIONS

15:50 PV Audit & Inspections - Preparation, implementation and lessons to be learnt

- Major and a vital role Monitoring PV compliance
- PV Inspection readiness: What to expect? How ready can we be?
- PV Compliance: PV is at the Center but cannot do it alone. How to mobilize internal and external stakeholders?
- Risk based selection criteria for auditing
- Methodologies, scope and oversight
- Relationship to other GxPs

REGULATORY

16:20 Panel Discussion: The developing regulatory framework

- Current regulatory framework and its global impact What's new?
- What are the current regulatory and practical challenges of the Risk Management Plan and how can you identify potential improvements?
- PV Laws, Regulations, Guidelines and Best Practices
- How do marketing authorisation holders ensure they are upto-date with current legal regulatory regulations and guidelines?
- Up-to-date information on all aspects of compliance in pharmacovigilance (both pre-marketing and post-marketing) The effect of Browit on Pharmacovicilance
- The effect of Brexit on Pharmacovigilance

Moderator:

BEN LOCWIN President Healthcare Science Advisors

Panellists:

TEGINDER SINGH Senior Director Global Regulatory Affairs Johnson & Johnson

SHEETAL KHEDKAR Senior Director, Regulatory Science Sarah Cannon Development Innovations

STEPHEN F. AMATO Faculty Director Graduate Regulatory Affairs, Market Access and Life Sciences Northeastern University

17:00 - 17:10 - Chairperson's closing remarks and end of conference

"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

> 02nd - 04th October 2018, Double Tree Suites By Hilton Boston, Cambridge, Massachusetts, USA

"Conference was very informative & added much knowledge about Pharmacovigilance systems, ADE, process flow of reporting, searching data & mobile networking"

Asst. Manager Regulatory Affairs, Emcure Pharmaceuticals

DAY THREE - 04th October 2018

FOR SPONSORSHIP OPPORTUNITIES:-

Sponsorship or exhibition is the best way to speed network with decision makers. The world leader speakers in our conferences attract niche delegates from all over the world. This would be a wonderful opportunity to reach the right audience and save money and time on all your other advertising gimmicks. To give you an advertising edge we constantly update the industry pioneers via emails/news letter about the event and advertise the event via different forms of media.

Sponsorship Enquires - sponsor.uk@virtueinsight.com



Organized by




189 London Road Croydon, Surrev CR0 2DR **(**) +44-2036120886

"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

> 02nd - 04th October 2018, Double Tree Suites By Hilton Boston, Cambridge, Massachusetts, USA

AGENDA AT A GLANCE

FLOOR PLAN - Book your stalls now before they run out !!!



Organized by

🐓 Virtue Insight

29 Gary Court, 189 London Road Croydon, Surrey CR0 2DR

info.uk@virtueinsight.com

+44-2036120886

"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

> 02nd - 04th October 2018, Double Tree Suites By Hilton Boston, Cambridge, Massachusetts, USA

"Panel discussions are very interactive as well as address real world and practical issues."

Head - Medical Affairs, Wockhardt

Organized by

Virtue

Delegate Details:		FOR BANK TRANSFER:
Title Mr Mrs Mrs Dr		Account Name - Virtue Insight Events Ltd
First Name		Account Number - 53278603
Surname		Bank Name - Barclays Bank PLC Sort Code - 20-84-20
Company		SWIFT Code: BARCGB22 IBAN Code: GB36BARC20842053278603
Position		ROUTING Code: 026002574
Address		Special Offer:
Pincode		3 for 2 Offer
Telephone		*Only few more seats left
Fax		TERMS AND CONDITIONS:
Email		
How to Pay (Choose one of the following payment options)		Payment terms: Virtue Insight requires the full amount to be paid before the conference. We may refuse entry to delegates who have not paid their invoice in full.
RESERVATION PRICING:		Cancellations: Delegates and vendor are subject to the following charges and refunds upon withdrawal or cancellation.Between 2-3 month's prior 75% cancellation fee/ 25% refund.Less than 2 months prior to the event Full cancellation fee / No refund.
Super Early Bird (Valid till 5th July 2018)		Administration Fee: If you cancel your participation (once confirmed)
Conference Only - £799 per delegate		and haven't paid the attendance fee you will be liable to pay an admin- istration fee of £ 200
Conference + Workshop - £999 per delegate Workshop Only - £250		 Substitutions/Name Change: If you are unable to attend you may nom- inate, in writing, another delegate to take your place at any time prior to the start of the event. This can be done at not extra cost.
PAYMENT:		Presentation: If you cannot attend the conference, you can still purchase
Please send me ar	n invoice	the presentations for £ 400
I enclose a cheque for £ Please charge my card £		Indemnity: Virtue Insight reserves the right to make alterations to the conference/executive briefing content, timing, speakers or venue with-
		out notice. The event may be postponed or cancelled due to unforeseen events beyond the control of Virtue Insight. If such a situation arises, we
Card Number		will refund your registration fee and we will try to reschedule the event
Security No		Fee: The conference fee includes lunch, refreshments and conference papers provided on the day. This fee does not include travel or hote
Expiry Date		accommodation.
Cardholder's Nar	ne	VENUE
Cardholder's Reg	istered Address	Double Tree Suites By Hilton
		Boston
Signature		Address: 400 Soldiers Field Rd, Boston MA 02134
Our purchase ord	er no.is	Boston, MA 02134, USA
Payable to Virtue Insight Events Ltd		Phone: +44 61 7783 0090
Card type: Visa	Mastercard Maestro Amex	
		MAP & DIRECTIONS
0	29 Gary Court, 189 London Road,	
it.	189 London Road, Croydon, Surrey CR0 2DR	